Chapter 8 150 References 1. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before totalmesorectal excision (TME) versus preoperative chemoradiotherapy, TME, andoptional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. 2. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCERPRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–715. 3. Borstlap WAA, Tanis PJ, Koedam TWA, et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer.;16 . Epub ahead of print July 21, 2016. DOI: 10.1186/S12885-016-2557-X. 4. Bach SP, Sebag-Montefiore D, deWilt H, et al. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)?Protocol for the international,multicentre, rollingphase II/III partially randomised patient preference trial evaluating long course concurrent chemoradiotherapy versus short course radiotherapy organ preservation approaches. Colorectal Dis. . Epub ahead of print February 3, 2022. DOI: 10.1111/CODI.16056. 5. Mohiuddin M, Lingareddy V, Rakinic J, et al. Reirradiation for rectal cancer and surgical resection after ultra high doses. Int J Radiat Oncol. 1993;27:1159–1163. 6. MohiuddinM, MarksG, Marks J. Long-termresults of reirradiation for patientswith recurrent rectal carcinoma. Cancer. 2002;95:1144–1150. 7. Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64:1129–1139. 8. Dresen RC, Gosens MJ, Martijn H, et al. Radical Resection After IORT-Containing Multimodality Treatment is the Most Important Determinant for Outcome in Patients Treated for Locally Recurrent Rectal Cancer. Ann Surg Oncol. . Epub ahead of print 2008. DOI: 10.1245/s10434-0089896-z. 9. Bosman SJ, Holman FA, Nieuwenhuijzen GAP, et al. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg. 2014;101:1280–1289. 10. Holman FA, Bosman SJ, Haddock MG, et al. Results of a pooled analysis of IOERT containing multimodality treatment for locally recurrent rectal cancer: Results of 565 patients of two major treatment centres. Eur J Surg Oncol. 2017;43:107–117. 11. Guren MG, Undseth C, Rekstad BL, et al. Reirradiation of locally recurrent rectal cancer: A systematic review. Radiother Oncol. 2014;113:151–157. 12. Van Der Meij W, Rombouts AJM, Rutten H, et al. Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients: AReview. Diseases of the Colon and Rectum. 2016;59:148– 156. 13. Sorrentino L, Belli F, Valvo F, et al. Neoadjuvant (re)chemoradiation for locally recurrent rectal cancer: Impact of anatomical site of pelvic recurrence on long-termresults. SurgOncol. 2020;35:89– 96. 14. van Zoggel DMGI, Bosman SJ, Kusters M, et al. Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer. Br J Surg. 2018;105:447–452.
RkJQdWJsaXNoZXIy MTk4NDMw